Artera develops AI-enabled predictive and prognostic cancer tests to personalize therapy decisions for prostate cancer patients. The ArteraAI Prostate Test analyzes digital pathology images and clinical data to forecast therapeutic benefit and patient prognosis. This precision medicine approach empowers clinicians with data to guide individualized treatment intensification for localized prostate cancer.
Funding
$110M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Localized prostate cancer treatment decisions are often made using conventional techniques that may not fully capture the heterogeneity of the disease, leading to potential over- or under-treatment. Current risk stratification methods may not accurately predict which patients will benefit from specific therapies. This can result in suboptimal treatment plans and outcomes for men with localized prostate cancer.
Solution
ArteraAI has developed a multimodal artificial intelligence (MMAI) test that analyzes digital pathology images and clinical data to provide personalized treatment guidance for localized prostate cancer patients. The ArteraAI Prostate Test leverages a clinically validated algorithm to predict therapy benefit and determine prognosis by assessing digital images from a patient’s biopsy and learning from clinical data. The test analyzes multiple characteristics of the individual patient, accomplishing tasks that conventional techniques and computers cannot do alone. The AI-driven insights empower physicians to make more informed treatment decisions, allowing for a more personalized approach to cancer therapy.
Target Audience
The primary audience includes oncologists and urologists treating localized prostate cancer, as well as patients seeking personalized treatment plans.
Features
- AI-enabled analysis of digital pathology images and clinical data
- Prediction of therapy benefit and long-term outcomes
- Does not consume tissue; uses existing pathology slides that are digitized for AI analysis
- Results are available within 2-3 days after receipt of the patient's specimen
- Standardized report provides both predictive and prognostic results
- Models developed with cohorts comprising about 20% African American patients